Nusano and PharmaLogic will collaborate to advance the development of radiopharmaceuticals for diagnostic and therapeutic applications.
Nusano Announces In-House Stable Isotope Program Led by Renowned Physicist Sarko Cherekdjian
Nusano is creating an in-house stable isotope program to enhance the company’s medical radioisotope production capabilities and decrease dependence on foreign supply chains.
Nusano to Participate in the 2nd Annual Guggenheim Securities Radiopharmaceuticals Day
Nusano, Inc., a company reshaping the production of cancer-fighting radioisotopes, today announced it will participate in a fireside chat at the 2nd Annual Guggenheim Securities Radiopharmaceuticals Day in New York City on Monday, May 15, 2023.
Nusano to Host Key Opinion Leader Webinar on Isotope Production and Applications for Oncology Radio-pharmaceuticals
Nusano is hosting a virtual Key Opinion Leader (KOL) event on Friday, May 12, 2023 at 10 a.m. EST. The event will highlight the rapidly expanding and critically undersupplied medical radioisotopes market, including current limitations and what must be overcome to improve patient care and unlock market potential.
Nusano to Present Production Capabilities to European Radiopharmaceuticals Working Group
Nusano will present an overview of the company’s breakthrough production platform to the European Cooperation in Science and Technology (COST) Astatine-211 Working Group on May 4, 2023. Presentation materials will be available on the company’s website following the event.
Nusano Co-Founder Dr. Howard Lewin to Participate in Truist Securities Virtual Radiopharmaceuticals Event
Nusano’s Dr. Howard Lewin will take part in a virtual event hosted by Truist Securities on Friday, April 21, 2023, at 3:30 p.m. Eastern.
DISCOVER MORE ABOUT NUSANO
Sign up to receive company news and updates